Targeting inflammatory pathways to treat atherosclerosis and cancer

Ridker, P. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1707914 (2017)

Ridker, P. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32247-X (2017)